TY - JOUR
T1 - Surgery for neck recurrence of differentiated thyroid cancer
T2 - Outcomes and risk factors
AU - Lamartina, Livia
AU - Borget, Isabelle
AU - Mirghani, Haitham
AU - Al Ghuzlan, Abir
AU - Berdelou, Amandine
AU - Bidault, François
AU - Deandreis, Desiree
AU - Baudin, Eric
AU - Travagli, Jean Paul
AU - Schlumberger, Martin
AU - Hartl, Dana M.
AU - Leboulleux, Sophie
N1 - Publisher Copyright:
Copyright © 2017 by the Endocrine Society.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background: Persistent/recurrent disease in the neck is frequent in patients with differentiated thyroid cancer (DTC). Objective: Assess efficacy, safety, and prognostic factors of first neck reoperation in DTC. Methods: Retrospective study of consecutive patients undergoing neck reoperation for recurrent/ persistent DTC in a referral cancer center. Response after reoperation was defined according to the 2015 American Thyroid Association guidelines. Findings: One hundred sixty-one DTC patients were enrolled (64% females, median age 35 years, 96% papillary DTC). Initial stage was pT3 in 43% and pT4 in 10%, pN1 in 74%. Aggressive histology was present in 25% of the patients, in both primary and persistent/recurrent tumor. Four patients had no malignancy in the reoperative specimen, and 1 patient died due to postoperative hematoma and was excluded from further analysis. Following reoperation, 15 patients (10%) had persistent structural disease, 16 (10%) had biochemical incomplete response, 26 (17%) had indeterminate response, and 99 (63%) had complete response (CR), among whom 24 relapsed later. After a median follow-up of 5 years, only 83 patients (53%) had CR without the need for further treatments. The rate of permanent complications was: hypoparathyroidism 2%, laryngeal nerve palsy 0.6%, other 6%.Age45 years, aggressive histology, and lymph node ratio0.6 at initial surgerywere independent risk factors for incomplete response after reoperation. Male sex, aggressive histology, and 10 metastases at reoperation were independent risk factors of secondary relapse following CR achieved with reoperation. Conclusion: A careful risk-benefit analysis should guide surgical decision, particularly in patients with risk factors for incomplete response.
AB - Background: Persistent/recurrent disease in the neck is frequent in patients with differentiated thyroid cancer (DTC). Objective: Assess efficacy, safety, and prognostic factors of first neck reoperation in DTC. Methods: Retrospective study of consecutive patients undergoing neck reoperation for recurrent/ persistent DTC in a referral cancer center. Response after reoperation was defined according to the 2015 American Thyroid Association guidelines. Findings: One hundred sixty-one DTC patients were enrolled (64% females, median age 35 years, 96% papillary DTC). Initial stage was pT3 in 43% and pT4 in 10%, pN1 in 74%. Aggressive histology was present in 25% of the patients, in both primary and persistent/recurrent tumor. Four patients had no malignancy in the reoperative specimen, and 1 patient died due to postoperative hematoma and was excluded from further analysis. Following reoperation, 15 patients (10%) had persistent structural disease, 16 (10%) had biochemical incomplete response, 26 (17%) had indeterminate response, and 99 (63%) had complete response (CR), among whom 24 relapsed later. After a median follow-up of 5 years, only 83 patients (53%) had CR without the need for further treatments. The rate of permanent complications was: hypoparathyroidism 2%, laryngeal nerve palsy 0.6%, other 6%.Age45 years, aggressive histology, and lymph node ratio0.6 at initial surgerywere independent risk factors for incomplete response after reoperation. Male sex, aggressive histology, and 10 metastases at reoperation were independent risk factors of secondary relapse following CR achieved with reoperation. Conclusion: A careful risk-benefit analysis should guide surgical decision, particularly in patients with risk factors for incomplete response.
UR - http://www.scopus.com/inward/record.url?scp=85015200477&partnerID=8YFLogxK
U2 - 10.1210/jc.2016-3284
DO - 10.1210/jc.2016-3284
M3 - Article
C2 - 28359102
AN - SCOPUS:85015200477
SN - 0021-972X
VL - 102
SP - 1020
EP - 1031
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 3
ER -